SG11201503271XA - Compositions and methods for modulating cell signaling - Google Patents

Compositions and methods for modulating cell signaling

Info

Publication number
SG11201503271XA
SG11201503271XA SG11201503271XA SG11201503271XA SG11201503271XA SG 11201503271X A SG11201503271X A SG 11201503271XA SG 11201503271X A SG11201503271X A SG 11201503271XA SG 11201503271X A SG11201503271X A SG 11201503271XA SG 11201503271X A SG11201503271X A SG 11201503271XA
Authority
SG
Singapore
Prior art keywords
compositions
methods
cell signaling
modulating cell
modulating
Prior art date
Application number
SG11201503271XA
Inventor
Timothy Alan Springer
Leonard Ira Zon
Nagesh K Mahanthappa
Original Assignee
Scholar Rock Inc
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc, Childrens Medical Center filed Critical Scholar Rock Inc
Publication of SG11201503271XA publication Critical patent/SG11201503271XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201503271XA 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling SG11201503271XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722919P 2012-11-06 2012-11-06
US201261722969P 2012-11-06 2012-11-06
PCT/US2013/068613 WO2014074532A2 (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Publications (1)

Publication Number Publication Date
SG11201503271XA true SG11201503271XA (en) 2015-05-28

Family

ID=50685303

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201503271XA SG11201503271XA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling
SG10201704616SA SG10201704616SA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201704616SA SG10201704616SA (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Country Status (10)

Country Link
US (2) US20150284455A1 (en)
EP (1) EP2916867A4 (en)
JP (3) JP2016500704A (en)
AU (3) AU2013341353B2 (en)
CA (2) CA2890733A1 (en)
IL (1) IL238488B (en)
MX (1) MX2015005675A (en)
SG (2) SG11201503271XA (en)
WO (1) WO2014074532A2 (en)
ZA (1) ZA201502884B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
PL2202245T3 (en) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
ES2563483T3 (en) 2008-04-11 2016-03-15 Chugai Seiyaku Kabushiki Kaisha Antigen binding molecule capable of repeatedly binding to two or more antigen molecules
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
CA2882272C (en) 2012-08-24 2023-08-29 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc region variant
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
EP2982689B1 (en) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
CN107073090A (en) 2014-04-30 2017-08-18 哈佛学院董事会 With reference to vaccine device and kill cancer cell method
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MX2017006167A (en) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use.
SG11201700841QA (en) * 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
CN107108729A (en) 2015-02-05 2017-08-29 中外制药株式会社 The antibody of antigen-binding domains comprising ion concentration dependence, FC region variants, the binding antibodies of IL 8, and its application
JP2018527903A (en) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． GDF11 binding protein and use thereof
KR20230155021A (en) * 2015-09-15 2023-11-09 스칼러 락, 인크. Anti-pro/latent-myostatin antibodies and uses thereof
IL258322B2 (en) 2015-09-24 2023-10-01 Daiichi Sankyo Co Ltd Anti-garp antibodies, nucleotides encoding same, vectors, cells and compositions comparising same, methods of producing same and uses thereof
MX2018005061A (en) 2015-11-12 2019-02-28 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use.
JP7141336B2 (en) 2015-12-25 2022-09-22 中外製薬株式会社 Anti-myostatin antibodies and methods of use
WO2017120523A2 (en) 2016-01-08 2017-07-13 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
CN115531609A (en) 2016-02-06 2022-12-30 哈佛学院校长同事会 Remodeling hematopoietic niches to reconstitute immunity
JP2019509737A (en) 2016-03-11 2019-04-11 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． TGFβ1-binding immunoglobulin and use thereof
EP4029518A1 (en) * 2016-03-31 2022-07-20 Jiangsu Yahong Meditech Co., Ltd. Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers
PE20190205A1 (en) 2016-06-13 2019-02-07 Scholar Rock Inc USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES
MA45738A (en) 2016-07-13 2019-05-22 Harvard College MIMETIC SCAFFOLDING OF ANTIGEN PRESENT CELLS AND METHODS FOR PREPARING AND USING THEM
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
CN109996817A (en) * 2016-09-15 2019-07-09 艾科赛扬制药股份有限公司 Reverse primitive gut embryogenesis polypeptide and application thereof
SI3565592T1 (en) 2017-01-06 2023-05-31 Scholar Rock, Inc. Treating metabolic diseases by inhibiting myostatin activation
AU2018255244A1 (en) 2017-04-21 2019-10-31 Mellitus, Llc Methods and antibodies for diabetes-related applications
CA3099260A1 (en) 2017-05-09 2018-11-15 Scholar Rock, Inc. Lrrc33 inhibitors and use thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3749365A4 (en) 2018-01-29 2022-01-12 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
RS62914B1 (en) 2018-07-11 2022-03-31 Scholar Rock Inc Isoform selective tgfbeta1 inhibitors and use thereof
TW202035445A (en) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 Anti-lap antibody variants and uses thereof
EP3689905A3 (en) 2019-01-30 2021-02-24 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta and uses thereof
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021030303A1 (en) 2019-08-12 2021-02-18 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
BR112022003412A2 (en) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Latent anti-tgf-beta 1 cross-species antibodies and methods of use
CN111474336B (en) * 2020-03-21 2023-07-28 南昌大学 Preparation method of nickel ferricyanide nanoparticle luminescent aptamer sensor and method for detecting 8-OhdG based on nickel ferricyanide nanoparticle luminescent aptamer sensor
WO2022099093A1 (en) * 2020-11-06 2022-05-12 President And Fellows Of Harvard College Scaffolds for enhancing neutrophils and uses thereof
JP2024501627A (en) 2020-12-14 2024-01-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Method for treating metabolic disorders and cardiovascular diseases using inhibin subunit βE (INHBE) inhibitors
CN113061575B (en) * 2021-03-25 2023-04-07 中国人民解放军陆军军医大学 Method for separating and purifying inherent lymphoid cells from colon inherent layer of old mouse
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CN115286701A (en) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 Target for regulating intestinal mucosa homeostasis or inflammatory bowel disease of mammals and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
JP3452946B2 (en) * 1992-02-19 2003-10-06 協和醗酵工業株式会社 Anti-TGF-β masking protein monoclonal antibody
AU5587094A (en) * 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
ATE186220T1 (en) * 1994-03-29 1999-11-15 Univ Manchester WOUND HEALING
US5616561A (en) * 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US20080206219A1 (en) * 2003-08-08 2008-08-28 The Regencts Of The University Of California Novel Indications for Transforming Growth Factor-Beta Regulators
WO2006106599A1 (en) * 2005-03-01 2006-10-12 Kyoto University Pharmaceutical for preventing and/or treating disease caused by abnormal enhancement of extracellular domain shedding
US8597646B2 (en) * 2005-10-25 2013-12-03 The Johns Hopkins University Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
WO2009114702A2 (en) * 2008-03-14 2009-09-17 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials

Also Published As

Publication number Publication date
AU2017203805A1 (en) 2017-06-22
US20200024339A1 (en) 2020-01-23
AU2017203805B2 (en) 2019-08-15
CA3023553A1 (en) 2014-05-15
AU2019264599A1 (en) 2019-12-05
JP2019163317A (en) 2019-09-26
EP2916867A4 (en) 2016-10-05
SG10201704616SA (en) 2017-07-28
AU2013341353B2 (en) 2017-03-16
IL238488A0 (en) 2015-06-30
AU2013341353A1 (en) 2015-05-28
WO2014074532A2 (en) 2014-05-15
EP2916867A2 (en) 2015-09-16
ZA201502884B (en) 2016-01-27
MX2015005675A (en) 2016-02-03
CA2890733A1 (en) 2014-05-15
WO2014074532A3 (en) 2014-06-26
JP2016500704A (en) 2016-01-14
US20150284455A1 (en) 2015-10-08
IL238488B (en) 2020-04-30
JP2017132796A (en) 2017-08-03

Similar Documents

Publication Publication Date Title
ZA201502884B (en) Compositions and methods for modulating cell signaling
HK1211623A1 (en) Cell lines
HK1212597A1 (en) Compositions for modulating c9orf72 expression c90rf72
ZA201409229B (en) Compositions and methods for modulating utrn expression
IL237156A0 (en) Microcapsule compositions and methods
EP2850184A4 (en) Compositions and methods for modulating gene expression
EP2850183A4 (en) Compositions and methods for modulating gene expression
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
EP2850189A4 (en) Compositions and methods for modulating gene expression
SG11201408697QA (en) Methods and compositions for natural killer cells
EP2906696A4 (en) Methods for modulating c9orf72 expression
EP2836212A4 (en) Novel compositions and methods
EP2850182A4 (en) Compositions and methods for modulating atp2a2 expression
ZA201300319B (en) Compositions and methods for modulating the wnt signaling pathway
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2850187A4 (en) Compositions and methods for modulating pten expression
EP2849800A4 (en) Compositions and methods for modulating bdnf expression
HK1205189A1 (en) Methods and compositions for modulating factor vii expression vii
EP2911230A4 (en) Cell
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
HK1220389A1 (en) Methods and compositions for modulating regulatory cell function
HK1210436A1 (en) Novel cell compositions and methods
EP2827861A4 (en) Composition and methods for cell modulation